Crewe Advisors LLC Regeneron Pharmaceuticals, Inc. Transaction History

Crewe Advisors LLC

$856 Million
Q1 2024

A detailed history of Crewe Advisors LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Crewe Advisors LLC holds 29 shares of REGN stock, worth $30,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$30,515

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$902.69 - $993.35 $26,178 - $28,807	29 New	29 $27,000
Q2 2023 Jul 28, 2023	SELL	$700.03 - $830.35 $4,200 - $4,982	-6 Reduced 85.71%	1 $0
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $4,082 - $4,961	-6 Reduced 46.15%	7 $5,000
Q4 2022 Feb 07, 2023	SELL	$705.89 - $766.39 $26,823 - $29,122	-38 Reduced 74.51%	13 $9,000
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $9,183 - $11,589	16 Added 45.71%	51 $35,000

Q2 2022 Aug 02, 2022	BUY	$548.35 - $738.84 $19,192 - $25,859	35 New	35 $21,000
Q4 2021 Feb 10, 2022	SELL	$543.48 - $670.97 $6,521 - $8,051	-12 Closed	0 $0
Q4 2020 Jan 27, 2021	SELL	$478.3 - $607.98 $5,261 - $6,687	-11 Reduced 47.83%	12 $6,000
Q3 2020 Oct 13, 2020	BUY	$544.75 - $658.21 $12,529 - $15,138	23 New	23 $13,000

Others Institutions Holding REGN

# of Institutions

1,427

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

Vanguard Group Inc Valley Forge, PA

8.93M
Shares

$9.4 Billion
0.17% of portfolio
Black Rock Inc. New York, NY

8.57M
Shares

$9.02 Billion
0.19% of portfolio
Jpmorgan Chase & CO New York, NY

7.73M
Shares

$8.13 Billion
0.68% of portfolio
State Street Corp Boston, MA

4.84M
Shares

$5.09 Billion
0.21% of portfolio
Capital World Investors Los Angeles, CA

4.65M
Shares

$4.9 Billion
0.76% of portfolio

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $113B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.

Account